

# Massimo Bernardi

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3034035/publications.pdf>

Version: 2024-02-01

86  
papers

5,362  
citations

126708

33  
h-index

85405

71  
g-index

87  
all docs

87  
docs citations

87  
times ranked

6248  
citing authors

#	ARTICLE	IF	CITATIONS
1	Loss of Mismatched HLA in Leukemia after Stem-Cell Transplantation. <i>New England Journal of Medicine</i> , 2009, 361, 478-488.	13.9	459
2	Infusion of suicide-gene-engineered donor lymphocytes after family haploidentical haemopoietic stem-cell transplantation for leukaemia (the TK007 trial): a non-randomised phase II study. <i>Lancet Oncology</i> , 2009, 10, 489-500.	5.1	458
3	Improved risk classification for risk-specific therapy based on the molecular study of minimal residual disease (MRD) in adult acute lymphoblastic leukemia (ALL). <i>Blood</i> , 2009, 113, 4153-4162.	0.6	387
4	CD44v6-targeted T cells mediate potent antitumor effects against acute myeloid leukemia and multiple myeloma. <i>Blood</i> , 2013, 122, 3461-3472.	0.6	306
5	Immune signature drives leukemia escape and relapse after hematopoietic cell transplantation. <i>Nature Medicine</i> , 2019, 25, 603-611.	15.2	253
6	Nonmyeloablative conditioning followed by hematopoietic cell allografting and donor lymphocyte infusions for patients with metastatic renal and breast cancer. <i>Blood</i> , 2002, 99, 4234-4236.	0.6	209
7	Clinical Effects of Driver Somatic Mutations on the Outcomes of Patients With Myelodysplastic Syndromes Treated With Allogeneic Hematopoietic Stem-Cell Transplantation. <i>Journal of Clinical Oncology</i> , 2016, 34, 3627-3637.	0.8	204
8	WHO classification and WPSS predict posttransplantation outcome in patients with myelodysplastic syndrome: a study from the Gruppo Italiano Trapianto di Midollo Osseo (GITMO). <i>Blood</i> , 2008, 112, 895-902.	0.6	192
9	Retroviral vector integration deregulates gene expression but has no consequence on the biology and function of transplanted T cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2006, 103, 1457-1462.	3.3	172
10	Antitumor effects of HSV-TK-engineered donor lymphocytes after allogeneic stem-cell transplantation. <i>Blood</i> , 2007, 109, 4698-4707.	0.6	171
11	Predictive factors for the outcome of allogeneic transplantation in patients with MDS stratified according to the revised IPSS-R. <i>Blood</i> , 2014, 123, 2333-2342.	0.6	162
12	Prognostic impact of pre-transplantation transfusion history and secondary iron overload in patients with myelodysplastic syndrome undergoing allogeneic stem cell transplantation: a GITMO study. <i>Haematologica</i> , 2010, 95, 476-484.	1.7	144
13	Transfer of the HSV-tk Gene into Donor Peripheral Blood Lymphocytes for In Vivo Modulation of Donor Anti-Tumor Immunity after Allogeneic Bone Marrow Transplantation. <i>The San Raffaele Hospital, Milan, Italy. Human Gene Therapy</i> , 1995, 6, 813-819.	1.4	137
14	Classification and Personalized Prognostic Assessment on the Basis of Clinical and Genomic Features in Myelodysplastic Syndromes. <i>Journal of Clinical Oncology</i> , 2021, 39, 1223-1233.	0.8	127
15	Immunological Outcome in Haploidentical-HSC Transplanted Patients Treated with IL-10-Anergized Donor T Cells. <i>Frontiers in Immunology</i> , 2014, 5, 16.	2.2	126
16	Post-transplantation Cyclophosphamide and Sirolimus after Haploidentical Hematopoietic Stem Cell Transplantation Using a Treosulfan-based Myeloablative Conditioning and Peripheral Blood Stem Cells. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1506-1514.	2.0	121
17	Sirolimus-based graft-versus-host disease prophylaxis promotes the in vivo expansion of regulatory T cells and permits peripheral blood stem cell transplantation from haploidentical donors. <i>Leukemia</i> , 2015, 29, 396-405.	3.3	114
18	Temporal, quantitative, and functional characteristics of single-KIR-positive alloreactive natural killer cell recovery account for impaired graft-versus-leukemia activity after haploidentical hematopoietic stem cell transplantation. <i>Blood</i> , 2008, 112, 3488-3499.	0.6	113

#	ARTICLE	IF	CITATIONS
19	Incidence, risk factors and clinical outcome of leukemia relapses with loss of the mismatched HLA after partially incompatible hematopoietic stem cell transplantation. <i>Leukemia</i> , 2015, 29, 1143-1152.	3.3	110
20	Autologous Pancreatic Islet Transplantation in Human Bone Marrow. <i>Diabetes</i> , 2013, 62, 3523-3531.	0.3	90
21	MATILDE regimen followed by radiotherapy is an active strategy against primary CNS lymphomas. <i>Neurology</i> , 2006, 66, 1435-1438.	1.5	83
22	Combined Treatment with High-Dose Methotrexate, Vincristine and Procarbazine, without Intrathecal Chemotherapy, Followed by Consolidation Radiotherapy for Primary Central Nervous System Lymphoma in Immunocompetent Patients. <i>Oncology</i> , 2001, 60, 134-140.	0.9	82
23	Optimal timing of allogeneic hematopoietic stem cell transplantation in patients with myelodysplastic syndrome. <i>American Journal of Hematology</i> , 2013, 88, 581-588.	2.0	61
24	Droplet digital polymerase chain reaction for DNMT3A and IDH1/2 mutations to improve early detection of acute myeloid leukemia relapse after allogeneic hematopoietic stem cell transplantation. <i>Haematologica</i> , 2016, 101, e157-e161.	1.7	55
25	MATRIxâ€“RICE therapy and autologous haematopoietic stem-cell transplantation in diffuse large B-cell lymphoma with secondary CNS involvement (MARIETTA): an international, single-arm, phase 2 trial. <i>Lancet Haematology</i> , 2021, 8, e110-e121.	2.2	54
26	Decision analysis of allogeneic hematopoietic stem cell transplantation for patients with myelodysplastic syndrome stratified according to the revised International Prognostic Scoring System. <i>Leukemia</i> , 2017, 31, 2449-2457.	3.3	51
27	Infections after Allogeneic Transplant with Post-Transplant Cyclophosphamide: Impact of Donor HLA Matching. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1179-1188.	2.0	49
28	Posttransplantation cyclophosphamide and sirolimus for prevention of GVHD after HLA-matched PBSC transplantation. <i>Blood</i> , 2016, 128, 1528-1531.	0.6	46
29	Enteric Microbiome Markers as Early Predictors of Clinical Outcome in Allogeneic Hematopoietic Stem Cell Transplant: Results of a Prospective Study in Adult Patients. <i>Open Forum Infectious Diseases</i> , 2017, 4, ofx215.	0.4	45
30	Allogeneic hematopoietic stem cell transplantation for neuromyelitis optica. <i>Annals of Neurology</i> , 2014, 75, 447-453.	2.8	43
31	Comparable outcomes of haploidentical, 10/10 and 9/10 unrelated donor transplantation in adverse karyotype AML in first complete remission. <i>American Journal of Hematology</i> , 2018, 93, 1236-1244.	2.0	40
32	Clinical Impact of Pretransplant Multidrug-Resistant Gram-Negative Colonization in Autologous and Allogeneic Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1476-1482.	2.0	39
33	Human Herpesvirus 6 Infection Following Haploidentical Transplantation: Immune Recovery and Outcome. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 2250-2255.	2.0	36
34	High rate of hematological responses to sorafenib in FLT3-ITD acute myeloid leukemia relapsed after allogeneic hematopoietic stem cell transplantation. <i>European Journal of Haematology</i> , 2016, 96, 629-636.	1.1	35
35	Control of infectious mortality due to carbapenemase-producing <i>Klebsiella pneumoniae</i> in hematopoietic stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2017, 52, 114-119.	1.3	33
36	Updated risk-oriented strategy for acute lymphoblastic leukemia in adult patients 18â€“65 years: NILG ALL 10/07. <i>Blood Cancer Journal</i> , 2020, 10, 119.	2.8	29

#	ARTICLE	IF	CITATIONS
37	Pre-transplant 18F-FDG-PET predicts outcome in lymphoma patients treated with high-dose sequential chemotherapy followed by autologous stem cell transplantation. <i>Leukemia and Lymphoma</i> , 2008, 49, 727-733.	0.6	27
38	Wilms' Tumor Gene 1 Transcript Levels in Leukapheresis of Peripheral Blood Hematopoietic Cells Predict Relapse Risk in Patients Autografted for Acute Myeloid Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1586-1591.	2.0	26
39	Posttransplantation Cyclophosphamide- and Sirolimus-Based Graft-Versus-Host-Disease Prophylaxis in Allogeneic Stem Cell Transplant. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 776.e1-776.e13.	0.6	26
40	Real-world experience with decitabine as a first-line treatment in 306 elderly acute myeloid leukaemia patients unfit for intensive chemotherapy. <i>Hematological Oncology</i> , 2019, 37, 447-455.	0.8	25
41	Interleukin-6 as Biomarker for Acute GvHD and Survival After Allogeneic Transplant With Post-transplant Cyclophosphamide. <i>Frontiers in Immunology</i> , 2019, 10, 2319.	2.2	25
42	Allogeneic stem cell transplantation in therapy-related acute myeloid leukemia and myelodysplastic syndromes: impact of patient characteristics and timing of transplant. <i>Leukemia and Lymphoma</i> , 2012, 53, 96-102.	0.6	24
43	Rapamycin Induces a Caspase-Independent Cell Death in Human Monocytes. <i>American Journal of Transplantation</i> , 2006, 6, 1331-1341.	2.6	23
44	Graft-versus-leukemia Effect of HLA-haploidentical Central-memory T-cells Expanded With Leukemic APCs and Modified With a Suicide Gene. <i>Molecular Therapy</i> , 2013, 21, 466-475.	3.7	23
45	Randomized trial comparing standard vs sequential high-dose chemotherapy for inducing early CR in adult AML. <i>Blood Advances</i> , 2019, 3, 1103-1117.	2.5	23
46	Hematological improvement during iron-chelation therapy in myelodysplastic syndromes: The experience of the Rete Ematologica Lombarda. <i>Leukemia Research</i> , 2013, 37, 1233-1240.	0.4	20
47	Clinical management of peripherally inserted central catheters compared to conventional central venous catheters in patients with hematological malignancies: A large multicenter study of the REL-GROUP (Rete Ematologica Lombarda - Lombardy Hematologic Network, Italy). <i>Journal of Clinical Oncology</i> , 2019, 37, 1197-1204.	2.0	19
48	Allogeneic stem cell transplantation for the treatment of advanced solid tumors. <i>Seminars in Immunopathology</i> , 2004, 26, 95-108.	4.0	18
49	M4 acute myeloid leukemia: the role of eosinophilia and cytogenetics in treatment response and survival. The GIMEMA experience. <i>Haematologica</i> , 2008, 93, 1025-1032.	1.7	18
50	Long-term follow-up of metastatic renal cancer patients undergoing reduced-intensity allografting. <i>Bone Marrow Transplantation</i> , 2009, 44, 237-242.	1.3	18
51	Microbiome markers are early predictors of acute GVHD in allogeneic hematopoietic stem cell transplant recipients. <i>Blood</i> , 2021, 137, 1556-1559.	0.6	18
52	Clinical significance of chromatin-spliceosome acute myeloid leukemia: a report from the Northern Italy Leukemia Group (NILG) randomized trial 02/06. <i>Haematologica</i> , 2021, 106, 2578-2587.	1.7	15
53	Missing HLA C group 1 ligand in patients with AML and MDS is associated with reduced risk of relapse and better survival after allogeneic stem cell transplantation with fludarabine and treosulfan reduced toxicity conditioning. <i>American Journal of Hematology</i> , 2017, 92, 1011-1019.	2.0	14
54	Genomic typing for patient-specific human leukocyte antigen-alleles is an efficient tool for relapse detection of high-risk hematopoietic malignancies after stem cell transplantation from alternative donors. <i>Leukemia</i> , 2008, 22, 2119-2122.	3.3	12

#	ARTICLE	IF	CITATIONS
55	Validation of the "fitness criteria" for the treatment of older patients with acute myeloid leukemia: A multicenter study on a series of 699 patients by the Network Rete Ematologica Lombarda (REL). <i>Journal of Geriatric Oncology</i> , 2021, 12, 550-556.	0.5	12
56	Early recovery of CMV immunity after HLA-haploidentical hematopoietic stem cell transplantation as a surrogate biomarker for a reduced risk of severe infections overall. <i>Bone Marrow Transplantation</i> , 2015, 50, 1262-1264.	1.3	11
57	Adjuvant role of SeptiFast to improve the diagnosis of sepsis in a large cohort of hematological patients. <i>Bone Marrow Transplantation</i> , 2018, 53, 410-416.	1.3	10
58	A New Clinicobiological Scoring System for the Prediction of Infection-Related Mortality and Survival after Allogeneic Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 2151-2158.	2.0	9
59	The place of ceftazidime/avibactam and ceftolozane/tazobactam for therapy of haematological patients with febrile neutropenia. <i>International Journal of Antimicrobial Agents</i> , 2021, 57, 106335.	1.1	9
60	Treosulfan-Based Conditioning Regimen Prior to Allogeneic Stem Cell Transplantation: Long-Term Results From a Phase 2 Clinical Trial. <i>Frontiers in Oncology</i> , 2021, 11, 731478.	1.3	8
61	Ruxolitinib for chronic steroid-refractory graft versus host disease: a single center experience. <i>Leukemia Research</i> , 2021, 109, 106642.	0.4	8
62	The influence of disease and comorbidity risk assessments on the survival of MDS and oligoblastic AML patients treated with 5-azacitidine: A retrospective analysis in ten centers of the "Rete Ematologica Lombarda". <i>Leukemia Research</i> , 2016, 42, 21-27.	0.4	7
63	SARS-CoV-2 in Myelodysplastic Syndromes: A Snapshot From Early Italian Experience. <i>HemaSphere</i> , 2020, 4, e483.	1.2	7
64	Letermovir reduces chronic GVHD risk in calcineurin inhibitor-free GVHD prophylaxis after hematopoietic cell transplantation. <i>Blood Advances</i> , 2022, 6, 3053-3057.	2.5	7
65	Haploidentical HSCT: a 15-year experience at San Raffaele. <i>Bone Marrow Transplantation</i> , 2015, 50, S67-S71.	1.3	6
66	Coadministration of posaconazole and sirolimus in allogeneic hematopoietic stem cell transplant recipients. <i>Bone Marrow Transplantation</i> , 2016, 51, 1022-1024.	1.3	6
67	Treosulfan based reduced toxicity conditioning followed by allogeneic stem cell transplantation in patients with myelofibrosis. <i>Hematological Oncology</i> , 2016, 34, 154-160.	0.8	6
68	Longitudinal qPCR monitoring of nucleophosmin 1 mutations after allogeneic hematopoietic stem cell transplantation to predict AML relapse. <i>Bone Marrow Transplantation</i> , 2016, 51, 466-469.	1.3	6
69	Long-term quality of life of patients with acute promyelocytic leukemia treated with arsenic trioxide vs chemotherapy. <i>Blood Advances</i> , 2021, 5, 4370-4379.	2.5	5
70	Integrating a prospective pilot trial and patient-derived xenografts to trace metabolic changes associated with acute myeloid leukemia. <i>Journal of Hematology and Oncology</i> , 2016, 9, 115.	6.9	4
71	Rapid and Wide Immunoreconstitution Obtained with HSV-TK Engineered Donor Lymphocyte Add-Backs Permits Long-Term Survival after haplo-HSCT. <i>Blood</i> , 2006, 108, 307-307.	0.6	4
72	Allogeneic hematopoietic stem cell transplantation in patients older than 65 years with acute myeloid leukemia and myelodysplastic syndrome: a 15-year experience. <i>Bone Marrow Transplantation</i> , 2022, 57, 678-680.	1.3	4

#	ARTICLE	IF	CITATIONS
73	Mono-oligoclonal immunoglobulin abnormalities in diabetic patients after kidney transplantation: influence of simultaneous pancreas graft. <i>Diabetologia</i> , 1998, 41, 1176-1179.	2.9	3
74	Human T cells engineered with a leukemia lipid-specific TCR enables donor-unrestricted recognition of CD1c-expressing leukemia. <i>Nature Communications</i> , 2021, 12, 4844.	5.8	3
75	Locoregional intrasplenic chemotherapy for hypersplenism in myelofibrosis. <i>British Journal of Haematology</i> , 2001, 114, 638-640.	1.2	2
76	Bone marrow mammaglobin expression as a marker of graft-versus-tumor effect after reduced-intensity allografting for advanced breast cancer. <i>Bone Marrow Transplantation</i> , 2006, 37, 311-315.	1.3	2
77	Postâ€remission intensive treatment after induction chemotherapy is feasible in selected elderly patients with acute myeloid leukemia and age â€75 years: A retrospective analysis of the <sc>R</sc>ete <sc>E</sc>matologica <sc>L</sc>ombarda. <i>American Journal of Hematology</i> , 2015, 90, E123-5.	2.0	2
78	Elderly patientsâ€65 years of age with acute myeloid leukemia and normal karyotype benefit from intensive therapeutic programs. <i>American Journal of Hematology</i> , 2016, 91, E302-3.	2.0	2
79	Molecular remission at the end of treatment is a necessary goal for a good outcome in ELN favorable-risk acute myeloid leukemia: a real-life analysis on 201 patients by the Rete Ematologica Lombarda network. <i>Annals of Hematology</i> , 2018, 97, 2107-2115.	0.8	2
80	Validating the Patient's "Fitness" Criteria Proposed to Guide Treatment Decision in Elderly AML: a Multicenter Study on a Population-Based Series of 362 Patients By the Network "Rete Ematologica Lombarda" (REL). <i>Blood</i> , 2014, 124, 279-279.	0.6	2
81	Nanosphere's VerigeneÂ® Blood Culture Assay to Detect Multidrug-Resistant Gram-Negative Bacterial Outbreak: A Prospective Study on 79 Hematological Patients in a Country with High Prevalence of Antimicrobial Resistance. <i>Clinical Hematology International</i> , 2019, 1, 120-123.	0.7	2
82	Secondary acute myeloid leukaemia in elderly patients: Patient's fitness criteria and ELN prognostic stratification can be applied to guide treatment decisions. An analysis of 280 patients by the network rete ematologica lombarda (REL). <i>American Journal of Hematology</i> , 2018, 93, E54-E57.	2.0	1
83	Coadministration of letermovir and sirolimus in allogeneic hematopoietic cell transplant recipients. <i>Bone Marrow Transplantation</i> , 2021, , .	1.3	1
84	Decision Analysis of Allogeneic Stem Cell Transplantation in Patients with Myelodysplastic Syndrome Stratified According to the Who Classification-Based Prognostic Scoring System (WPSS). <i>Blood</i> , 2011, 118, 116-116.	0.6	1
85	Autologous Pancreatic Islet Transplantation in Human Bone Marrow. <i>Diabetes</i> 2013;62:3523-3531. <i>Diabetes</i> , 2014, 63, 377-377.	0.3	0
86	Prevalence and Prognostic Role of IDH Mutations in Acute Myeloid Leukemia: Results of the GIMEMA AML1516 Protocol. <i>Cancers</i> , 2022, 14, 3012.	1.7	0